Analyst Reco. OncoCyte Corporation

Equities

OCX

US68235C2061

Delayed Nasdaq Other stock markets 01:43:44 2024-04-19 pm EDT			5-day change	1st Jan Change
2.49 ^USD	-2.73%		-8.12%	-0.40%

Apr. 16	Broadwood Capital, Inc. Engages with OncoCyte Corporation	CI
Apr. 12	Sector Update: Health Care Stocks Steady Pre-Bell Friday	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Needham Adjusts Price Target on OncoCyte to $3.60 From $4.25, Maintains Buy Rating	Nov. 09	MT
Benchmark Adjusts Price Target on OncoCyte to $5 From $9, Maintains Speculative Buy Rating	23-08-24	MT
Piper Sandler Adjusts Price Target on OncoCyte to $3.50 From $6, Keeps Neutral Rating	23-08-15	MT
Needham Adjusts OncoCyte's Price Target to $4.25 From $9, Keeps Buy Rating	23-08-10	MT
Needham Trims Price Target on OncoCyte to $0.45 From $1.40, Keeps Buy Rating	23-04-04	MT
Lake Street Downgrades Oncocyte to Hold From Buy, Cuts Price Target to $0.50 From $3	22-12-01	MT
Piper Sandler Downgrades OncoCyte to Neutral From Overweight, Adjusts Price Target to $0.50 From $1	22-11-18	MT
Piper Sandler Trims Price Target on OncoCyte to $1 From $1.50, Maintains Overweight Rating	22-11-14	MT
Lake Street Adjusts OncoCyte Price Target to $3 From $6, Maintains Buy Rating	22-08-11	MT
Needham Trims OncoCyte's Price Target to $2.10 From $2.25 on 'Lower Revenue Estimates;' Buy Rating Kept	22-08-11	MT
Stephens Downgrades OncoCyte to Equalweight From Overweight, Adjusts Price Target to $1.25 From $2	22-05-24	MT
Piper Sandler Trims OncoCyte's Price Target to $1.40 From $1.80, Maintains Overweight Rating	22-05-16	MT
Needham Adjusts OncoCyte's Price Target to $2.25 From $4 on 'Peer Multiple Compression,' Reiterates Buy Rating	22-05-12	MT
Piper Sandler Adjusts OncoCyte's Price Target to $1.80 from $3.10, Keeps Overweight Rating	22-03-18	MT
KeyBanc Downgrades OncoCyte to Sector Weight From Overweight, Citing Need for Added Capital, Removes $7 Price Target	22-03-14	MT
Lake Street Adjusts OncoCyte Price Target to $6 From $11, Maintains Buy Rating	22-03-11	MT
Needham Adjusts OncoCyte's Price Target to $4 From $5, Citing Peer Multiple Compression; Buy Rating Kept	22-03-11	MT
Stephens Initiates OncoCyte With Overweight Rating, $3.10 Price Target	22-01-07	MT
Stephens Starts OncoCyte at Overweight With $3.10 Price Target	22-01-07	MT
Needham Lowers OncoCyte's Price Target to $5 From $7, Maintains Buy Rating	21-12-15	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. OncoCyte Corporation

Equities

OCX

US68235C2061

Analyst Reco.

Filters